Biotinylated Human LILRB1 / CD85j / ILT2 Protein, Fc,Avitag?
分子別名（Synonym）
CD85J,LILRB1,CD85,ILT2,LIR1,MIR7
表達區(qū)間及表達系統(tǒng)（Source）
Biotinylated Human LILRB1, Fc,Avitag (CDJ-H82F7) is expressed from human 293 cells (HEK293). It contains AA Gly 24 - His 458 (Accession # D9IDM8-1).
Predicted N-terminus: Gly 24
蛋白結(jié)構(gòu)（Molecular Characterization）
This protein carries a human IgG1 Fc tag at the C-terminus, followed by a Avi tag (Avitag?).
The protein has a calculated MW of 75.6 kDa. The protein migrates as 100-116 kDa under reducing (R) condition, and 150 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.
標記（Labeling）
Biotinylation of this product is performed using Avitag? technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白標記度（Protein Ratio）
Passed as determined by the HABA assay / binding ELISA.
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
純度（Purity）
>95% as determined by SDS-PAGE.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景（Background）
LILRB1（Uniprot No.D9IDM8-1）是一種與NK細胞上LILRB1低表達相關(guān)的變體。它反映了LILRB1基因座的多樣性及其對NK細胞表達模式的影響。LILRB1屬于LIR受體的B亞家族，其包含兩個或四個細胞外免疫球蛋白結(jié)構(gòu)域、一個跨膜結(jié)構(gòu)域和兩到四個細胞質(zhì)免疫受體酪氨酸基抑制基序（ITIM）。受體在免疫細胞上表達，與抗原呈遞細胞上的MHC I類分子結(jié)合，并傳遞抑制免疫反應(yīng)刺激的負信號。它被認為可以控制炎癥反應(yīng)和細胞毒性，以幫助集中免疫反應(yīng)并限制自身反應(yīng)性。
關(guān)鍵字： LILRB1;LILRB1蛋白;LILRB1重組蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學等。